Dengue vaccine under the microscope: will it keep kids out of the hospital?
NCT ID NCT06843226
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether the dengue vaccine (TDV) helps prevent hospital stays due to dengue in children and teens in Thailand, Indonesia, and Malaysia. Researchers will follow 70,000 participants for 3 years, comparing those who got the vaccine with those who did not. The goal is to gather real-world data on how well the vaccine works, especially against less common dengue types.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could confirm that the dengue vaccine effectively prevents severe dengue leading to hospitalization in children and teens.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also limited to specific countries and may not apply everywhere.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 70,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2025
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Pediatric and/or adolescent residents in the study area who are age-eligible for vaccination with TDV as part of a pilot public vaccination program (children 7-10 years in Thailand, 6-10 years in Indonesia, and 7-12 years in Malaysia).
- Ages
-
6 to 12 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Cohort: To be eligible for inclusion in the study cohort, participants must meet the following inclusion criteria: 1. The participant is a child or adolescent eligible to be vaccinated with TDV as part of a vaccination program planned in the study area. 2. The participant's family do not intend to migrate away from the cohort hospital catchment area within 3 years of his/her enrollment into the study cohort. 3. The participant's parent(s) or legally acceptable representative (LAR) signs and dates a written informed consent form (ICF), and any required privacy authorization where applicable, prior to the initiation of any study procedures, after the nature of the study has been explained according to local regulatory requirements. 4. The participant signs and dates an age-appropriate assent form prior to the initiation of any study procedures, after the nature of the study has been explained according to local regulatory requirements. 5. The participant's parent(s) or LAR agrees that a baseline blood sample may be taken from the participant. Cases: To be eligible for inclusion as a case, participants must meet the following inclusion criteria: 1. The participant is part of the cohort. 2. The participant is hospitalized and clinically diagnosed with dengue. 3. The participant has a blood sample available that was taken preferably within 5 days of fever onset and/or onset of symptoms compatible with dengue. 4. The participant tested positive for dengue by RT-PCR. Controls: To be eligible for inclusion as a matched control, participants must meet the following inclusion criteria: 1. The participant is part of the cohort. 2. The participant had not been hospitalized with VCD at any point between enrollment in the cohort and the index date (that is, when his/her matched case was hospitalized with CDD). 3. The participant is a resident in the same neighbourhood as the matched case. 4. The participant's date of birth is in the same calendar year as the matched case. Exclusion Criteria Cases: To be eligible for inclusion as a case participants must not meet any of the following criteria: 1. The participant has been vaccinated with TDV, a tetravalent, live attenuated, chimeric dengue vaccine in a yellow fever 17D backbone (CYD-TDV), or an investigational dengue vaccine prior to cohort enrollment. 2. Contraindications as per the locally approved label/product information leaflet. Controls: To be eligible for inclusion as a control participants must not meet any of the following criteria: 1. The participant has been vaccinated with TDV, CYD-TDV, or an investigational dengue vaccine prior to cohort enrollment. 2. Contraindications as per the locally approved label/product information leaflet. 3. The participant could not be contacted at the time of being selected as a control.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Dengue fever are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
4 sites in 2 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Fakultas Kedokteran Lambung Mangkurat
RECRUITINGBanjarmasin, South Kalimantan, 70122, Indonesia
-
Fakultas Kedokteran Universitas Indonesia
RECRUITINGJakarta Pusat, 10430, Indonesia
-
Fakultas Kedokteran Universitas Sriwijaya
RECRUITINGPalembang, South Sumatra, 30662, Indonesia
-
Nakhon Phanom Hospital
ACTIVE_NOT_RECRUITINGNakhon Phanom, 48000, Thailand
-
Pattaya Patamakhun Hospital
ACTIVE_NOT_RECRUITINGChon Buri, 20150, Thailand
-
Phra Nakhon Si Ayutthaya Hospital
ACTIVE_NOT_RECRUITINGPhra Nakhon Si Ayutthaya, 13000, Thailand
-
Universiti Malaya Medical Centre
NOT_YET_RECRUITINGKuala Lumpur, 59100, Malaysia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill shorten dengue? trial tests resomelagon
- Can a dengue vaccine be both Cost-Effective and trusted? a thai study investigates
- Dengue vaccine booster put to the test: can it shield against all four virus types?
- Flu drug zanamivir tested against Dengue's deadliest complication
- AI toolkit aims to speed up epidemic response for diseases like COVID-19 and mpox
- Could a new vaccine shield infants from dengue?